Recent Updates
Recently added Catalysts

Maze Therapeutics, Inc.

MAZEFDA catalysts, PDUFA dates & pipeline intelligence
$32.87
▼ -1.03 · -3.04%

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full MAZE financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $21.9552W HIGH $53.65
Volume
601.75 K
Value Traded
19.80 M
Short % Float
19.69%
Days to Cover
8.8
-10.51%Week
+10.67%1 Month
+10.49%3 Month
+31.32%6 Month
+59.93%5 Year
+59.93%All Time

Cash Data

Unlock MAZE cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
1.80 B
EPS (TTM)
-2.77
P/E Ratio
-
Ent. Value
1.36 B
Total Shares
54.68 M
Float Shares
33.95 M
Insiders
37.91%
Institutions
74.00%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
Phase 2 data readout
MZE829
APOL1-Mediated Kidney Disease (AMKD)
Phase 2Small MoleculesNephrology
Unlock every MAZE catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

MAZE Catalyst Timeline

Dated clinical, regulatory and corporate events for Maze Therapeutics, Inc.

Catalyst Timeline

Dated clinical, regulatory & corporate events for Maze Therapeutics, Inc.

89Total events
15Upcoming
10Tier-1 (high impact)
2024 to 2029Coverage

Upcoming catalysts 2

T3Additional Data
Subscribe to view catalyst details
MZE829
T1Topline Readout
Subscribe to view catalyst details
MZE829

Event history 50

●Quarterly UpdateCorporate
Third Quarter 2026 financial results reported
●Oral PresentationMZE829Presentation
Oral presentation of Phase 2 HORIZON data for MZE829 at ASN Kidney Week
APOL1-mediated kidney disease (AMKD)source ↗
●Poster PresentationMZE782Presentation
Two preclinical posters on MZE782 SLC6A19 inhibition in CKD at ASN Kidney Week
Chronic kidney disease (CKD)source ↗
●Enrollment UpdateMZE829Trial
Enrollment in Phase 2 HORIZON trial of MZE829 on track
▲Trial InitiationMZE782Trial
Phase 2 CIPheR trial of MZE782 in PKU initiated
●Management ChangeCorporate
Appointments of Paula Johnson and Sophie Kornowski to Board of Directors
◆Trial InitiationMZE782Trial
Initiation of Phase 2 proof-of-concept trial of MZE782 in CKD
chronic kidney disease (CKD)source ↗
▲Enrollment CompleteMZE829Trial
Enrollment completed in Phase 2 HORIZON trial of MZE829 in AMKD
APOL1-mediated kidney disease (AMKD)source ↗
◆Oral PresentationPresentation
Maze Therapeutics presentation at Goldman Sachs 47th Annual Global Healthcare Conference 2026
◆Oral PresentationPresentation
Maze Therapeutics presentation at 2026 Jefferies Global Healthcare Conference
Unlock the full MAZE catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How MAZE actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
2026-10-24MZE829 Phase 2 data presentation Phase 2
Unlock 2 more MAZE historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

Pipeline Score
Pipeline Value
Valuation Signal
3
Drugs Scored
rNPV / MCap
Top Drug
Top 39%
Micro Cap
(rank 283 of 725)
Percentile Rank
Showing 3 of 3 assets
DrugIndicationPhasePTRSrNPVStatusEnrollVelocityDesignEst. CompletionML SignalLast Change
MZE829 Small MoleculesNCT06830629Proteinuric Kidney DiseasePhase 2 RECRUITING 74Sep 1, 2026
MZE782 Small MoleculesNCT07694440Phenylketonuria (PKU)Phase 2 RECRUITING 38Feb 1, 2028
MZE001 Small MoleculesCompletedNCT05249621UndisclosedPhase 1 COMPLETED 121Dec 21, 2022
Unlock the MAZE pipeline intelligence model
PTRS, rNPV, enrollment velocity, trial design quality and ML risk signals for every asset above.
Institutional-grade data · Cancel anytime

Clinical Trial Results

Readouts, endpoints and source filings for every MAZE program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
MZE829 APOL1-mediated kidney diseasePhase 22026-10-06encouraging clinical activity in patients with AMKDRead MoreMaze Therapeutics to Present Data from MZE829 and MZE782 Programs at ASN Kidney Week 2026Read More
Scroll for more · summaries link to the source press release
Unlock every MAZE trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock MAZE insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
Coloma Jason VDirector, Officer (Chief Executive Officer)Sell -2,257 13,301 held$30.12 11/02/2026
Unlock the full MAZE insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Fund % of Portfolio Current MV Shares Owned Activity
Frazier Life Sciences Management, L.P. 3.6 % (9.1 %) 143.59 M 5.28 M 4.97% ( 250.00 K)
Unlock every fund holding MAZE
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in MAZE
Shares held by hedge funds each quarter, and who bought or sold.

Ownership Trends

Sign in to see MAZE ownership
Insider and institutional ownership, quarter by quarter.

MAZE Short Interest

Shares sold short, counted twice a month.

19.69%
Short % of Float
of tradable shares sold short
6.7M
Shares Sold Short
-11.2% vs prior count
8.8 High
Days to Cover
trading days of normal volume to buy every short share back
763.5K
Avg Daily Volume
the average used for days to cover
Unlock MAZE short interest history
Two years of days to cover and shares sold short, with every count and its change.
Institutional-grade data · Cancel anytime

Options Data

Option Volume

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
2026-11-20
Unlock MAZE option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live MAZE option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock MAZE options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How MAZE ranks across every disease it competes in

Competitive Position is a premium feature
See how MAZE ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

MAZE News

MAZE
Nov 9, 2026
MAZEPhases

Maze Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights

Maze Therapeutics reported its Q3 2026 financial results, highlighting the completion of enrollment in the Phase 2 HORIZON trial for MZE829. The company anticipates data from this trial in early 2027. Additionally, Maze is progressing with MZE782 in ongoing trials for PKU and CKD, with plans for further trials in 2027. The company's financial position remains strong with $477 million in cash.

Read more →
MAZE
Nov 3, 2026
MAZEConferences/Events
▲ +6.2%on this news

Maze Therapeutics to Participate in Upcoming Investor Conferences

Maze Therapeutics announced participation in three upcoming investor conferences. CEO Jason Coloma will engage in a fireside chat at the Guggenheim Healthcare Innovation Conference on November 10, 2026. He will also present at the Jefferies Global Healthcare Conference in London on November 17, 2026, and at the Evercore Healthcare Conference on December 1, 2026.

Read more →
MAZE
Oct 6, 2026
MAZEConferences/Events

Maze Therapeutics to Present Data from MZE829 and MZE782 Programs at ASN Kidney Week 2026

Maze Therapeutics will present data from its MZE829 and MZE782 programs at ASN Kidney Week 2026. The oral presentation will focus on updated Phase 2 HORIZON trial results for MZE829 in patients with APOL1-mediated kidney disease. Additionally, two poster presentations will discuss preclinical research on SLC6A19 inhibition's therapeutic potential for chronic kidney disease.

Read more →
MAZE
Sep 2, 2026
MAZEConferences/Events

Maze Therapeutics to Participate in Three Upcoming Investor Conferences

Maze Therapeutics, a clinical-stage biopharmaceutical company, will participate in three investor conferences in September 2026. The events include the Wells Fargo Annual Healthcare Conference, Citi Biopharma Summit, and H.C. Wainwright Global Investment Conference. Live webcasts of these presentations will be available on their website. The company is developing precision medicines targeting kidney and metabolic diseases.

Read more →
MAZE
Aug 13, 2026
MAZEGeneral

Maze Therapeutics Announces Appointments to Its Board of Directors

Maze Therapeutics has appointed Paula Johnson, M.D., and Sophie Kornowski, Pharm.D., to its Board of Directors. These appointments aim to enhance the company's clinical and business expertise as it advances its pipeline, including key milestones for drug candidates MZE829 and MZE782 expected in the coming years. The company focuses on developing precision medicines for kidney and metabolic diseases.

Read more →
MAZE
Aug 11, 2026
MAZEPhases

Maze Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights

Maze Therapeutics reported a net loss of $44.7 million for the second quarter ended June 30, 2026. The company holds $495 million in cash and marketable securities to fund operations through 2029. Enrollment in the Phase 2 HORIZON trial for MZE829 remains on track. Data from all cohorts is expected in late 2026 or early 2027.

Read more →
MAZE
May 27, 2026
MAZEConferences/Events

Maze Therapeutics to Participate in Two Upcoming Investor Conferences

Maze Therapeutics, a clinical-stage biopharmaceutical company, announced its participation in two upcoming investor conferences. CEO Jason Coloma will present at the Jefferies Global Healthcare Conference on June 3, 2026, and at the Goldman Sachs Global Healthcare Conference on June 10, 2026. The company is known for developing precision medicines for kidney and metabolic diseases.

Read more →
MAZE
May 13, 2026
MAZEGeneral

Maze Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights

Maze Therapeutics reported positive topline data from its Phase 2 HORIZON trial of MZE829, supporting its advancement into pivotal trials. The company is also on track to initiate Phase 2 trials for MZE782 targeting PKU and CKD. With a strong cash position of $528 million, Maze aims to continue its clinical execution through 2029.

Read more →
MAZE
Apr 22, 2026
MAZEGeneral

Maze Therapeutics Announces $150 Million Registered Offering

Maze Therapeutics announced a $150 million registered offering of its common stock at $23.50 per share. The offering includes pre-funded warrants and is expected to close on April 23, 2026. The funds will primarily be used for the development of MZE829 and MZE782, targeting kidney and metabolic diseases. The offering has attracted both new and existing investors.

Read more →
MAZE
Mar 25, 2026
MAZEGeneral
▼ -35.2%on this newsshared move

Maze Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights

Maze Therapeutics reported strong financial results for Q4 and full year 2025, highlighting positive topline data from the Phase 2 HORIZON trial of MZE829 for APOL1-mediated kidney disease. The company plans to advance MZE829 into a pivotal program and initiate two Phase 2 trials for MZE782 in PKU and CKD in 2026. Additionally, Neil Kumar has joined the Board of Directors, enhancing the company's leadership.

Read more →
MAZE
Mar 25, 2026
MAZEPhases
▼ -35.2%on this newsshared move

Maze Therapeutics Announces Positive Topline Data from Phase 2 HORIZON Trial of MZE829 Demonstrating the First Clinical Proof-of-Concept in Patients with Broad APOL1-Mediated Kidney Disease

Maze Therapeutics announced positive topline data from the Phase 2 HORIZON trial of MZE829, showing a significant mean reduction in proteinuria in patients with broad APOL1-mediated kidney disease. At week 12, MZE829 led to a 35.6% reduction in uACR, with half of the patients achieving greater than 30% reduction. The treatment was well-tolerated, and the company plans to advance MZE829 into a pivotal program.

Read more →
MAZE
Feb 25, 2026
MAZEConferences/Events

Maze Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference

Maze Therapeutics, a clinical-stage biopharmaceutical company, will present at the TD Cowen 46th Annual Health Care Conference on March 4, 2026. CEO Jason Coloma, Ph.D., will lead the presentation, which will also be available via live webcast. The company focuses on developing precision medicines for kidney and metabolic diseases.

Read more →
MAZE
Feb 4, 2026
MAZEConferences/Events

Maze Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

Maze Therapeutics will present at the Guggenheim Emerging Outlook: Biotech Summit 2026, showcasing its advancements in precision medicines for kidney and metabolic diseases. CEO Jason Coloma will speak on February 11, 2026. The company is known for its innovative approach using human genetics to develop treatments, with key products in Phase 2 development.

Read more →
MAZE
Jan 5, 2026
MAZEConferences/Events

Maze Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Maze Therapeutics will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026. CEO Jason Coloma, Ph.D., will discuss the company's advancements in small molecule precision medicines for kidney and metabolic diseases. The event will be available via live webcast and archived for 30 days.

Read more →
MAZE
Nov 6, 2025
MAZEGeneral

Maze Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights

Maze Therapeutics reported strong financial results for Q3 2025, highlighting positive first-in-human data from its Phase 1 trial of MZE782. The company plans to initiate two Phase 2 trials in 2026 for MZE782 targeting phenylketonuria and chronic kidney disease. Additionally, the ongoing Phase 2 HORIZON trial of MZE829 is expected to provide topline data by the end of Q1 2026.

Read more →
MAZE
Nov 6, 2025
MAZEConferences/Events

Maze Therapeutics to Present Additional Data Highlighting the Advancement of MZE829 and MZE782 Programs at ASN Kidney Week

Maze Therapeutics announced seven presentations at ASN Kidney Week, showcasing advancements in their MZE782 and MZE829 programs. MZE782, a novel SLC6A19 inhibitor, is in Phase 1 trials for PKU and CKD, while MZE829 is in Phase 2 for APOL1-mediated kidney disease. The company emphasizes the importance of genetic insights in developing effective therapies.

Read more →
MAZE
Nov 4, 2025
MAZEConferences/Events

Maze Therapeutics to Participate in Four Upcoming Investor Conferences

Maze Therapeutics announced that its management will participate in four upcoming investor conferences. The company will present at the Guggenheim Healthcare Innovation Conference on November 11. Additional appearances are scheduled for the TD Cowen Immunology Summit on November 13. The Jefferies Global Healthcare Conference follows on November 20, and the Evercore Healthcare Conference is set for December 3.

Read more →
MAZE
Oct 6, 2025
MAZEGeneral

Maze Therapeutics Appoints Industry Veteran Hervé Hoppenot as Chairman of the Board of Directors

Maze Therapeutics has appointed Hervé Hoppenot as the new Chairman of the Board, succeeding Charles Homcy, M.D. Hoppenot, who has extensive experience in the biopharmaceutical industry, expressed his commitment to advancing the company's clinical programs, particularly MZE782 and MZE829. The company is well-positioned for growth with recent funding and promising clinical data.

Read more →
MAZE
Sep 11, 2025
MAZEGeneral
▲ +54.8%on this news

Maze Therapeutics Announces Oversubscribed $150.0 Million Private Placement

Maze Therapeutics has announced a successful oversubscribed private placement, raising approximately $150 million. The funds will be used to further develop its lead candidates, MZE829 and MZE782, targeting kidney and metabolic diseases. The placement involves participation from both new and existing investors and is set to close on September 12, 2025.

Read more →
MAZE
Sep 11, 2025
MAZEPhases
▲ +54.8%on this newsshared move

Maze Therapeutics Announces Positive First-in-Human Results from Phase 1 Trial of MZE782, Establishing Proof of Mechanism for a Potent, Oral SLC6A19 Inhibitor with Potential to Treat Phenylketonuria (PKU) and Chronic Kidney Disease (CKD)

Maze Therapeutics announced positive Phase 1 trial results for MZE782, an oral SLC6A19 inhibitor. The trial demonstrated significant increases in urinary phenylalanine excretion and a favorable safety profile, supporting its advancement to Phase 2 trials for treating phenylketonuria (PKU) and chronic kidney disease (CKD) expected to start in 2026.

Read more →

About Maze Therapeutics, Inc.

South San Francisco, CA 141 employees mazetx.com
Headquarters171 OYSTER POINT BOULEVARD, SUITE 300, SOUTH SAN FRANCISCO, CA, 94080
BIOPHARMAWATCH ELITE
Trade the next MAZE catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime